Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-aflibercept and 5-FU in 3rd line metastatic colorectal cancer
NCT02235324Phase 2Withdrawn
- Sponsor
- University of Southern California
- Start
- Mar 2015
- Primary completion
- Mar 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in colorectal cancer (CRC), sponsored by University of Southern California. Planned start Mar 2015; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02235324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235324.